A health-care professional for more than two decades, Robert Hindes, MD of Connecticut attended Rutgers College in New Brunswick, New Jersey. Earning his bachelor of arts, he gained admission into the college’s medical school in nearby Piscataway, where he received an MD. Dr. Robert Hindes then completed an internship and residency at the Medical College of Pennsylvania Hospital and became board certified in internal medicine. Subsequently, he relocated to Boston, Massachusetts, where he completed a clinical and research infectious disease fellowship program at Harvard Medical School and New England Deaconess Hospital.

At the start of his career, Dr. Hindes joined the infectious disease group at Connecticut’s Danbury Hospital, consulting on inpatient infectious disease complications, and maintaining an outpatient consultative practice. His outstanding performance was highlighted in 2000, when he was named Attending Physician of the Year. Following a nearly 13-year tenure with Danbury hospital, Dr. Hindes accepted a position at Bristol Myers Squibb where he became medical lead for the hepatitis C anti-viral
development program, and then a role as vice president of clinical development at Pharmasset, which was later purchased by Gilead Sciences. At Pharmasset, Dr Hindes was responsible for developing Phase 2 and 3 clinical trials for sofosbuvir, now marketed as Sovaldi by Gilead. Following the acquisition of Pharmasset, Dr Hindes consulted for several companies developing treatment for hepatitis C and hepatitis B, including Biocryst, Oncore, Arrowhead, and Achillion.

Robert Hindes, MD, is currently Chief Medical Officer at Trek Therapeutics, a company he cofounded, and is responsible for strategic development and clinical operations.